Holen Sie sich die Stockscreener-App
1.56
20.41%
-0.40
Handel nachbörslich:
1.65
0.09
+5.77%
Schlusskurs vom Vortag:
$1.96
Offen:
$1.88
24-Stunden-Volumen:
2.11M
Relative Volume:
1.48
Marktkapitalisierung:
$252.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.6155
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
-33.62%
1M Leistung:
+95.91%
6M Leistung:
-19.17%
1J Leistung:
-87.65%
1-Tages-Spanne:
$1.515
$1.92
1-Wochen-Bereich:
$1.515
$2.3992
52-Wochen-Spanne:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
490 ARSENAL WAY, SUITE 200, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.56 | 317.03M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Does Neumora Therapeutics Inc. stock perform well during market downturnsCapitalize on fast-growing stocks today - jammulinksnews.com
How does Neumora Therapeutics Inc. generate profit in a changing economyCapitalize on market trends with expert guidance - jammulinksnews.com
What institutional investors are buying Neumora Therapeutics Inc. stockAchieve triple-digit returns with smart investing - jammulinksnews.com
What are the latest earnings results for Neumora Therapeutics Inc.Capitalize on market momentum for maximum profit - jammulinksnews.com
Why is Neumora Therapeutics Inc. stock attracting strong analyst attentionInvest confidently with professional guidance - jammulinksnews.com
Neumora Therapeutics to Report Q2 2025 Financial Results on August 6, 2025 - AInvest
What are analysts’ price targets for Neumora Therapeutics Inc. in the next 12 monthsAI Powered Tips With High Returns - jammulinksnews.com
How strong is Neumora Therapeutics Inc. company’s balance sheetExpert Picks Entry Points For 2025 - jammulinksnews.com
Neumora Therapeutics (NMRA) Expected to Post Earnings on Wednesday - MarketBeat
What is the dividend policy of Neumora Therapeutics Inc. stockPost Market Planner That Work - jammulinksnews.com
How many analysts rate Neumora Therapeutics Inc. as a “Buy”Chart Pattern Updates For Fast Growth - jammulinksnews.com
What are the technical indicators suggesting about Neumora Therapeutics Inc.Chart Pattern Guidance To Watch Now - jammulinksnews.com
Key metrics from Neumora Therapeutics Inc.’s quarterly dataTrade Insight With Community Collaboration Supported - metal.it
What are Neumora Therapeutics Inc. company’s key revenue driversAI Powered Planner Backed By Experts - jammulinksnews.com
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionStrong Buy With Technical Confidence Supported - beatles.ru
Published on: 2025-07-30 12:15:41 - metal.it
Mizuho Boosts Neumora Price Target to $5, Maintains Outperform Rating - AInvest
Pegasystems Delivers Strong Q2 Results, Raises Price Target to $58 - AInvest
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - Insider Monkey
Published on: 2025-07-29 01:24:00 - metal.it
What is Neumora Therapeutics Inc. company’s growth strategyNavigate market volatility with smart strategies - jammulinksnews.com
How volatile is Neumora Therapeutics Inc. stock compared to the marketRecord-setting profit potential - jammulinksnews.com
When is Neumora Therapeutics Inc. stock expected to show significant growthCapitalize on market trends with expert guidance - jammulinksnews.com
Is it the right time to buy Neumora Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com
Is Neumora Therapeutics Inc. a good long term investmentFree Investment Community - PrintWeekIndia
Neumora Therapeutics Inc. Stock Analysis and ForecastExponential wealth increase - PrintWeekIndia
What drives Neumora Therapeutics Inc. stock priceHigh-yield growth strategies - PrintWeekIndia
Is Neumora Therapeutics Inc. stock overhyped or has real potentialExceptional portfolio growth - jammulinksnews.com
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) PT at $7.14 - MarketBeat
Neumora Soared 24.33%—What Sparked This Volcanic Rally in a Biotech Underdog? - AInvest
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 - The Manila Times
Neumora Therapeutics Announces Q2 2025 Financial Results, Business Update - AInvest
What analysts say about Neumora Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating - MSN
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):